Healthcare Exit Market Shifts Toward Capital Efficiency and Strategic Discipline

The healthcare exit market is undergoing a significant transformation, according to Jack Euston, co-founder and general partner at Fountain Health Partners. The market is now more selective than ever, favoring companies that prioritize capital efficiency and operational discipline over the well-funded growth narratives that dominated in 2021.

Euston notes that while the IPO window cracked open last year with exits from Hinge Health and Omada Health, it has not expanded much further. Hold periods remain extended, reflecting a cautious investor environment. However, this current reality does not necessarily reflect the future landscape for companies launching today or those looking to exit in the next few years.

The Current Exit Landscape

The shift in the healthcare exit market is evident in the types of companies that are attracting acquisitions and investments. According to Euston, "The market has moved from acquiring well-funded growth stories to focusing on workflow-embedded, margin-relevant businesses." This means that companies with a clear path to profitability and sustainable business models are more likely to secure favorable exit terms.

For instance, Hinge Health and Omada Health managed to go public last year due to their strong track records in digital health solutions. These companies had established themselves as key players in the market, integrating seamlessly into healthcare workflows and demonstrating significant margin improvements. However, such success stories are becoming rarer as investors become more discerning.

The current environment also reflects lessons learned from previous cycles. High-profile failures like Walmart Health's shutdown, Walgreens' write-down of VillageMD, and Amazon's challenges with One Medical have made strategic buyers more cautious. These experiences highlight the importance of disciplined investment and a focus on high-quality assets.

The Bottom Line

Looking ahead to 2028-2031, Euston believes that the market will be "meaningfully better than current headlines suggest" for strong companies. He predicts that much of the "challenged 2021 vintage" will have dropped off, leaving a more robust and disciplined ecosystem. Companies receiving funding today typically have cleaner capital structures and more realistic growth expectations, setting them up for success in the future.

Euston also anticipates an expansion in the buyer world for middle-market healthcare companies. Strategic buyers are becoming more selective but remain willing to pay premium prices for high-quality assets. The role of AI in this landscape cannot be overstated. Buyers are increasingly viewing AI not just as a feature but as an engine for margin expansion, further sharpening the divide between premium and non-premium assets.

While the current healthcare exit market is highly selective, it is also setting the stage for a more disciplined and efficient future. Companies that prioritize capital efficiency, operational discipline, and strategic integration are well-positioned to succeed in this evolving landscape. Investors should remain focused on these key attributes when evaluating potential investments in the healthcare sector.